ERBB2 and triple-negative breast carcinoma: However, the efficacy of ICIs combined with HER2-targeted therapy in HER2-positive advanced breast cancer seems to be unsatisfactory, unlike the significant roles of ICIs in advanced or early stage triple-negative breast cancer [34,36].